An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer

Bladder cancer is among the five most common cancers diagnosed in the Western world and causes significant mortality and morbidity rates in affected patients. Therapeutic options to treat the disease in advanced muscle-invasive bladder cancer (MIBC) include cystectomy and chemotherapy. Neoadjuvant cisplatin-based combination chemotherapy is effective in MIBC; however, it has not been widely adopted by the community. One reason is that many patients do not respond to neoadjuvant chemotherapy, and no biomarker currently exists to identify these patients. It is also not clear whether a strategy to sensitize chemoresistant patients may exist. We sought to identify cisplatin-resistance patterns in preclinical models of bladder cancer, and test whether treatment with the epigenetic modifier decitabine is able to sensitize cisplatin-resistant bladder cancer cell lines. Using a screening approach in cisplatin-resistant bladder cancer cell lines, we identified dysregulated genes by RNA sequencing (RNAseq) and DNA methylation assays. DNA methylation analysis of tumors from 18 patients receiving cisplatin-based chemotherapy was used to confirm in vitro results. Cisplatin-resistant bladder cancer cells were treated with decitabine to investigate epigenetic sensitization of resistant cell lines. Our results show that HOXA9 promoter methylation status is associated with response to cisplatin-based chemotherapy in bladder cancer cell lines and in metastatic bladder cancer. Bladder cancer cells resistant to cisplatin chemotherapy can be sensitized to cisplatin by the DNA methylation inhibitor decitabine. Our data suggest that HOXA9 promoter methylation could serve as potential predictive biomarker and decitabine might sensitize resistant tumors in patients receiving cisplatin-based chemotherapy.

[1]  S. Tommasi,et al.  HOX gene methylation status analysis in patients with hereditary breast cancer , 2012, Journal of Human Genetics.

[2]  J. Witjes,et al.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[3]  J. Karbach,et al.  The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. , 2010, Leukemia research.

[4]  Wun-Jae Kim,et al.  HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profiling , 2013, International journal of cancer.

[5]  H. Nishiyama,et al.  Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. , 2008, Urology.

[6]  Christoph Bock,et al.  DNA methylation biomarkers in cancer: progress towards clinical implementation , 2012, Expert review of molecular diagnostics.

[7]  M. Gore,et al.  A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer , 2014, British Journal of Cancer.

[8]  T. Ørntoft,et al.  Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation , 2012, PloS one.

[9]  J. Catto,et al.  Molecular mechanisms of cisplatin resistance in bladder cancer , 2012, Expert review of anticancer therapy.

[10]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[11]  C. Bokemeyer,et al.  Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia , 2011, American journal of hematology.

[12]  Richard D Emes,et al.  Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer , 2015, PloS one.

[13]  D. Albertson,et al.  Investigation of HOXA9 promoter methylation as a biomarker to distinguish oral cancer patients at low risk of neck metastasis , 2014, BMC Cancer.

[14]  A. Riggs,et al.  Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay , 2007, Proceedings of the National Academy of Sciences.

[15]  M. Parmar,et al.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. , 2005, European urology.

[16]  M. Benezra,et al.  HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. , 2010, The Journal of clinical investigation.

[17]  R. Claus,et al.  Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. , 2005, Seminars in oncology.

[18]  Gangning Liang,et al.  Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line , 2008, Proceedings of the National Academy of Sciences.

[19]  B. Oronsky,et al.  Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment , 2014, Anti-cancer agents in medicinal chemistry.

[20]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[21]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[22]  K. Bensalah,et al.  Challenges of cancer biomarker profiling. , 2007, European urology.

[23]  J. Issa,et al.  Decitabine dosing schedules. , 2005, Seminars in hematology.

[24]  T. Clozel,et al.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. , 2013, Cancer discovery.

[25]  Qinghua Wu,et al.  DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets , 2007, Molecular Cancer.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[28]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[29]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[30]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[31]  R. Humphries,et al.  Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells , 1999, Leukemia.

[32]  Y. Lotan,et al.  Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer , 2011, Cancer.